{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["antibody-drug conjugates", "doxorubicin", "epidermal growth factor receptor variant III", "glioblastoma", "single-chain antibodies"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38682116", "DateRevised": {"Year": "2024", "Month": "04", "Day": "30"}, "Article": {"Language": ["eng"], "ELocationID": ["254", "10.3892/etm.2024.12542"], "ArticleDate": [{"Year": "2024", "Month": "04", "Day": "17"}], "Journal": {"ISSN": "1792-1015", "JournalIssue": {"Volume": "27", "Issue": "6", "PubDate": {"Year": "2024", "Month": "Jun"}}, "Title": "Experimental and therapeutic medicine", "ISOAbbreviation": "Exp Ther Med"}, "ArticleTitle": "Preparation and evaluation of the PD0721\u2011DOX antibody\u2011drug conjugate targeting EGFRvIII to inhibit glioblastoma.", "Pagination": {"StartPage": "254", "MedlinePgn": "254"}, "Abstract": {"AbstractText": ["Epidermal growth factor receptor variant III (EGFRvIII) is prominently expressed in various epithelial tumors. PD0721, a single-chain antibody (scFv), has been developed to specifically target EGFRvIII. Although doxorubicin (DOX) is an essential treatment approach for glioblastoma (GBM), its toxic effects and limited targeting capabilities are a challenge. To overcome the above limitations, antibody-drug conjugates (ADCs) have been developed to exploit the specificity of monoclonal antibodies in directing potent cytotoxic drugs to tumor cells expressing the target antigens. The present study aimed to conjugate DOX with PD0721 scFv to construct a PD0721-DOX ADC targeting EGFRvIII and examine its targeting effect and <i>in vitro</i> anti-GBM activity. PD0721-DOX ADC was generated by combining PD0721 scFv with DOX, using dextran T-10 as a linker. The drug-to-antibody ratio (DAR) was measured by ultraviolet and visible spectrophotometry (UV-Vis). A series of techniques, including cytotoxicity assays, immunofluorescence, cell internalization and flow cytometry assays were employed to evaluate the targeting efficacy and anti-GBM activity of the PD0721-DOX ADC. Following the conjugation of PD0721 scFv with DOX, the UV-Vis results showed a noticeable red shift in the maximum absorbance. The DAR of PD0721 scFv and DOX was 9.23:1. Cytotoxicity assays demonstrated that DK-MG cells treatment with PD0721-DOX ADC at 10 and 20 \u00b5g/ml significantly increased cytotoxicity compared with U-87MG ATCC cells (all P<0.01). Confocal microscopy revealed distinct green and red fluorescence in EGFRvIII-expressing DK-MG cells, while no fluorescence was observed in EGFRvIII negative U-87MG ATCC cells. Furthermore, compared with U-87MG ATCC cells, DK-MG cells showed effective internalization of the PD0721-DOX ADC (P<0.001). Finally, flow cytometric analyses indicated that the PD0721-DOX ADC significantly promoted the apoptosis of DK-MG cells compared with U-87MG ATCC cells (P<0.01). In summary, the current study suggested that the PD0721-DOX ADC could exhibit a notable targeting efficacy and potent anti-GBM activity."], "CopyrightInformation": "Copyright: \u00a9 2024 Hu et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Hu", "ForeName": "Minmin", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Liu", "ForeName": "Hong", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Zhang", "ForeName": "Yubing", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Engineering Research Center for The Development and Application of Ethnic Medicine and TCM (Ministry of Education)/National Engineering Research Center of Miao's Medicines, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Lu", "ForeName": "Dingyan", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Zheng", "ForeName": "Lin", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Wang", "ForeName": "Yonglin", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Engineering Research Center for The Development and Application of Ethnic Medicine and TCM (Ministry of Education)/National Engineering Research Center of Miao's Medicines, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Chen", "ForeName": "Shuaishuai", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China."}], "LastName": "Liu", "ForeName": "Ting", "Initials": "T"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Greece", "MedlineTA": "Exp Ther Med", "NlmUniqueID": "101531947", "ISSNLinking": "1792-0981"}, "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020;70:299\u2013312. doi: 10.3322/caac.21613.", "ArticleIdList": ["10.3322/caac.21613", "32478924"]}, {"Citation": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Avazzadeh R, Vasheghani-Farahani E, Soleimani M, Amanpour S, Sadeghi M. Synthesis and application of magnetite dextran-spermine nanoparticles in breast cancer hyperthermia. Prog Biomater. 2017;6:75\u201384. doi: 10.1007/s40204-017-0068-8.", "ArticleIdList": ["10.1007/s40204-017-0068-8", "PMC5597569", "28624871"]}, {"Citation": "Tang L, Jiang WH, Wu L, Yu XL, He Z, Shan WG, Fu LL, Zhang ZH, Zhao YC. TPGS2000-DOX prodrug micelles for improving breast cancer therapy. Int J Nanomedicine. 2021;16:7875\u20137890. doi: 10.2147/IJN.S335405.", "ArticleIdList": ["10.2147/IJN.S335405", "PMC8647655", "34880613"]}, {"Citation": "Yang N, Ma HY, Jiang Z, Niu LH, Zhang XS, Liu YY, Wang YH, Cheng ST, Deng Y, Qi HY, Wang ZR. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2019;517:111\u2013117. doi: 10.1016/j.bbrc.2019.07.029.", "ArticleIdList": ["10.1016/j.bbrc.2019.07.029", "31303273"]}, {"Citation": "Aljobaily N, Viereckl MJ, Hydock DS, Aljobaily H, Wu TY, Busekrus R, Jones B, Alberson J, Han Y. Creatine alleviates doxorubicin-induced liver damage by inhibiting liver fibrosis, inflammation, oxidative stress and cellular senescence. Nutrients. 2020;13(41) doi: 10.3390/nu13010041.", "ArticleIdList": ["10.3390/nu13010041", "PMC7824063", "33374297"]}, {"Citation": "Guo Y, Ding YY, Zhang T, An HL. Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating FGFR4/FRS2\u03b1-ERK1/2 pathway-mediated NF-\u03baB activation. Phytomedicine. 2016;23:267\u2013273. doi: 10.1016/j.phymed.2015.12.017.", "ArticleIdList": ["10.1016/j.phymed.2015.12.017", "26969380"]}, {"Citation": "Santos EDS, Nogueira KAB, Fernandes LCC, Martins JRP, Reis AVF, Neto JBV, J\u00fanior I, Pessoa C, Petrilli R, Eloy JO. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm. 2021;592(120082) doi: 10.1016/j.ijpharm.2020.120082.", "ArticleIdList": ["10.1016/j.ijpharm.2020.120082", "33188892"]}, {"Citation": "Li MF, Yang JL, Zhang LH, Tu SF, Zhou X, Tan Z, Zhou WJ, He YJ, Li YH. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res. 2019;38(211) doi: 10.1186/s13046-019-1207-y.", "ArticleIdList": ["10.1186/s13046-019-1207-y", "PMC6532146", "31118055"]}, {"Citation": "Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3\u201320. doi: 10.1002/1878-0261.12155.", "ArticleIdList": ["10.1002/1878-0261.12155", "PMC5748484", "29124875"]}, {"Citation": "Hampton KK, Craven RJ. Pathways driving the endocytosis of mutant and wild-type EGFR in cancer. Oncoscience. 2014;1:504\u2013512. doi: 10.18632/oncoscience.67.", "ArticleIdList": ["10.18632/oncoscience.67", "PMC4278327", "25594057"]}, {"Citation": "Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DP. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 2010;116:3233\u20133243. doi: 10.1002/cncr.25073.", "ArticleIdList": ["10.1002/cncr.25073", "PMC2923448", "20564646"]}, {"Citation": "Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered. FEBS J. 2013;280:5350\u20135370. doi: 10.1111/febs.12393.", "ArticleIdList": ["10.1111/febs.12393", "23777544"]}, {"Citation": "Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA. Ligand-independent EGFR signaling. Cancer Res. 2015;75:3436\u20133441. doi: 10.1158/0008-5472.CAN-15-0989.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-0989", "PMC4558210", "26282175"]}, {"Citation": "Zheng Y, Ma Y, Yue H, Liu GZ, Han SY. EGFRvIII epigenetically regulates ARHI to promote glioma cell proliferation and migration. Exp Mol Pathol. 2020;112(104344) doi: 10.1016/j.yexmp.2019.104344.", "ArticleIdList": ["10.1016/j.yexmp.2019.104344", "31751560"]}, {"Citation": "Yang K, Ren X, Tao L, Wang P, Jiang H, Shen L, Zhao Y, Cui Y, Li M, Lin S. Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas. Chin J Cancer Res. 2019;31:188\u2013202. doi: 10.21147/j.issn.1000-9604.2019.01.14.", "ArticleIdList": ["10.21147/j.issn.1000-9604.2019.01.14", "PMC6433583", "30996577"]}, {"Citation": "Zhang Z, Jiang J, Wu X, Zhang M, Luo D, Zhang R, Li S, He Y, Bian H, Chen Z. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Front Med. 2019;13:57\u201368. doi: 10.1007/s11684-019-0683-y.", "ArticleIdList": ["10.1007/s11684-019-0683-y", "30721445"]}, {"Citation": "Bagley SJ, O'Rourke DM. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. Pharmacol Ther. 2020;205(107419) doi: 10.1016/j.pharmthera.2019.107419.", "ArticleIdList": ["10.1016/j.pharmthera.2019.107419", "31629009"]}, {"Citation": "Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(52) doi: 10.3390/cancers9050052.", "ArticleIdList": ["10.3390/cancers9050052", "PMC5447962", "28513565"]}, {"Citation": "Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: Clinical experience and latest developments. Target Oncol. 2017;12:719\u2013739. doi: 10.1007/s11523-017-0535-0.", "ArticleIdList": ["10.1007/s11523-017-0535-0", "29116596"]}, {"Citation": "Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15\u201329. doi: 10.1146/annurev-med-050311-201823.", "ArticleIdList": ["10.1146/annurev-med-050311-201823", "23043493"]}, {"Citation": "Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329\u20132340. doi: 10.1158/1535-7163.MCT-21-0206.", "ArticleIdList": ["10.1158/1535-7163.MCT-21-0206", "PMC9398094", "34413126"]}, {"Citation": "Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020;25(4764) doi: 10.3390/molecules25204764.", "ArticleIdList": ["10.3390/molecules25204764", "PMC7587605", "33081383"]}, {"Citation": "Zhang YB, Wu ZX, He B, Yang C, Li YJ, Liu T. Establishment and optimization of an ELISA for affinity detection of single-chain antibodies to EGFRvIII. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2021;37:73\u201378. (In Chinese)", "ArticleIdList": ["33441231"]}, {"Citation": "Zhang YB, Ye LF, Wu ZX, Xue WN, He B, Yang C, Li YJ, Wang YL, Liu T. Optimization and identification of prokaryotic expression conditions of PD0721 single-chain antibody in vitro. J Food Sci Biotech. 2021;40:42\u201349."}, {"Citation": "Struve N, Riedel M, Schulte A, Rieckmann T, Grob TJ, Gal A, Rothkamm K, Lamszus K, Petersen C, Dikomey E, Kriegs M. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells. Oncotarget. 2015;6:33867\u201333877. doi: 10.18632/oncotarget.5293.", "ArticleIdList": ["10.18632/oncotarget.5293", "PMC4741808", "26418954"]}, {"Citation": "Allen M, Bjerke M, Edlund H, Nelander S, Westermark B. Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 2016;8(354re3) doi: 10.1126/scitranslmed.aaf6853.", "ArticleIdList": ["10.1126/scitranslmed.aaf6853", "27582061"]}, {"Citation": "Zraik IM, He\u00df-Busch Y. Management of chemotherapy side effects and their long-term sequelae. Urologe A. 2021;60:862\u2013871. doi: 10.1007/s00120-021-01569-7. (In German)", "ArticleIdList": ["10.1007/s00120-021-01569-7", "34185118"]}, {"Citation": "Fu ZW, Li SJ, Han SF, Shi C, Zhang Y. Antibody drug conjugate: The \u2018biological missile\u2019 for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(93) doi: 10.1038/s41392-022-00947-7.", "ArticleIdList": ["10.1038/s41392-022-00947-7", "PMC8941077", "35318309"]}, {"Citation": "Hu QB, Lu YJ, Luo YC. Recent advances in dextran-based drug delivery systems: From fabrication strategies to applications. Carbohydr Polym. 2021;264(117999) doi: 10.1016/j.carbpol.2021.117999.", "ArticleIdList": ["10.1016/j.carbpol.2021.117999", "33910733"]}, {"Citation": "Helal MH, Al-Mudaris ZA, Al-Douh MH, Osman H, Wahab HA, Alnajjar BO, Abdallah HH, Abdul Majid AM. Diaminobenzene schiff base, a novel class of DNA minor groove binder. Int J Oncol. 2012;41:504\u2013510. doi: 10.3892/ijo.2012.1491.", "ArticleIdList": ["10.3892/ijo.2012.1491", "22614449"]}, {"Citation": "Marei HE, Cenciarelli C, Hasan A. Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022;22(255) doi: 10.1186/s12935-022-02679-8.", "ArticleIdList": ["10.1186/s12935-022-02679-8", "PMC9375290", "35964048"]}]}], "History": [{"Year": "2023", "Month": "9", "Day": "16"}, {"Year": "2024", "Month": "3", "Day": "6"}, {"Year": "2024", "Month": "4", "Day": "29", "Hour": "6", "Minute": "45"}, {"Year": "2024", "Month": "4", "Day": "29", "Hour": "6", "Minute": "44"}, {"Year": "2024", "Month": "4", "Day": "29", "Hour": "4", "Minute": "26"}, {"Year": "2024", "Month": "4", "Day": "17"}], "PublicationStatus": "epublish", "ArticleIdList": ["38682116", "PMC11046186", "10.3892/etm.2024.12542", "ETM-27-6-12542"]}}]}